Hls Therapeutics (TSE:HLS) has released an update.
HLS Therapeutics Inc. has reported an annual revenue of $63.1 million for fiscal 2023 with a slight increase from the previous year, alongside a growth in Canadian sales for its products. The company witnessed a robust 86% increase in Vascepa prescriptions and is focusing on operational execution and growth strategies, including an updated partnership with Pfizer for primary care. Despite a year of transitions, HLS is optimistic about profitability in 2024, particularly for its cardiovascular drug Vascepa.
For further insights into TSE:HLS stock, check out TipRanks’ Stock Analysis page.
